3) GILD might fit your item 3). Vascepa would complement its anti-inflammatory pipeline nicely, and lack of completion of Phase 3 results has not been an inhibiting factor in the past.
OTOH, in light of recent posts by others here, AZN fits the bill too for a partnership/acquisition. It entered a collaboration with PPHM within the past year(durvalumab?) in an immuno-therapy/oncology setting, combining with Bavituximab then in a phase 3 chemo-therapy trial. That last study is ongoing, with some top- line results to be presented at ESMO in early October.
News 
Market Data 
Discover 
